For rn-insulin for US market
Biocon announced that the Company through its wholly owned subsidiary Biocon SA, has entered into a co-development and commercialisation agreement with Laboratories PiSA S.A. de C.V (PiSA) of Mexico for generic recombinant human insulin (rh-insulin) for the US market. This is a cost and profit sharing agreement with Biocon SA being responsible for clinical development, regulatory approvals and commercialisation of the product in the US. The drug substance will be made by Biocon while the drug product will be made by PiSA at its facility in Mexico.Powered by Capital Market - Live News
